Clinic
Mercy Hospital Ardmore, INC.
Mercy Hospital Ardmore, INC. was paid $18.07M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is 99285, emergency room visit (most serious) — 36% of everything it billed.
33Billing provider infoMERCY HOSPITAL ARDMORE, INC.
ARDMORE, OK 73401
ARDMORE, OK 73401
33aNPI1386741635assigned 09/20/2006
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$18.07M
24GClaims221,599
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Oklahoma
Rank by total paid#4 of 33
Median peer was paid$609K
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,000 | $1.71M | |
| 2019 | 20,651 | $1.72M | |
| 2020 | 21,205 | $1.61M | |
| 2021 | 26,011 | $2.35M | |
| 2022 | 49,857 | $3.86M | |
| 2023 | 57,045 | $4.47M | |
| 2024incomplete | 25,830 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 36% | 19,810 | 19,526 | $6.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 26,312 | 26,024 | $4.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 14,515 | 14,390 | $3.54M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.4% | 8,849 | 8,726 | $1.15M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.4% | 3,165 | 3,145 | $427K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 1,876 | 1,862 | $322K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 5,448 | 5,268 | $228K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,429 | 21,360 | $145K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,063 | 11,943 | $145K |
| 80053 | Comprehensive metabolic panel | <1% | 15,635 | 14,986 | $136K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,001 | 640 | $136K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,017 | 521 | $111K |
102 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,753 | $85K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,041 | $81K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,392 | $65K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,780 | $60K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,579 | $50K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 543 | $49K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,181 | $47K |
| 83880 | <1% | 1,216 | $40K | |
| 62323 | <1% | 126 | $37K | |
| 84484 | <1% | 2,227 | $36K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 211 | $31K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 356 | $29K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 283 | $27K |
| 81001 | <1% | 10,134 | $27K | |
| 83690 | <1% | 4,149 | $25K | |
| 80306 | <1% | 1,568 | $22K | |
| 87081 | <1% | 3,252 | $19K | |
| 87653 | <1% | 558 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 182 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,033 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 847 | $12K |
| 84703 | <1% | 1,721 | $10K | |
| 80081 | <1% | 140 | $9K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,232 | $9K |
| 81025 | <1% | 1,261 | $9K | |
| 64483 | <1% | 22 | $9K | |
| 87070 | <1% | 981 | $8K | |
| 85610 | <1% | 2,180 | $8K | |
| 83735 | <1% | 1,353 | $7K | |
| 76801 | <1% | 128 | $7K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 192 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 840 | $6K |
| 84702 | <1% | 457 | $6K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 41 | $6K |
| 96367 | <1% | 176 | $6K | |
| 87807 | <1% | 432 | $5K | |
| 82728 | <1% | 395 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 125 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 125 | $4K |
| 81003 | <1% | 1,701 | $3K | |
| 80143 | <1% | 205 | $3K | |
| 80179 | <1% | 177 | $3K | |
| 86803 | <1% | 227 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 165 | $3K |
| 87400 | <1% | 99 | $2K | |
| 85379 | <1% | 288 | $2K | |
| 84144 | <1% | 132 | $2K | |
| 83655 | <1% | 201 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 43 | $2K |
| 85730 | <1% | 350 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 36 | $2K |
| 82731 | <1% | 30 | $2K | |
| 85027 | <1% | 269 | $1K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 25 | $1K |
| 72100 | <1% | 81 | $1K | |
| 83605 | <1% | 134 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $1K |
| 20610 | <1% | 15 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $890.78 |
| 82950 | <1% | 190 | $841.49 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 39 | $832.10 |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 17 | $584.83 |
| 86762 | <1% | 39 | $486.40 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $474.13 |
| 80061 | Lipid panel | <1% | 31 | $387.98 |
| 87340 | <1% | 39 | $358.41 | |
| 86592 | <1% | 93 | $345.80 | |
| 84439 | <1% | 41 | $336.81 | |
| 82803 | <1% | 13 | $324.66 | |
| 83615 | <1% | 64 | $319.51 | |
| 85014 | <1% | 143 | $310.08 | |
| 85018 | <1% | 143 | $310.08 | |
| 84156 | <1% | 88 | $264.97 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 28 | $256.70 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,399 | $250.17 |
| 84550 | <1% | 63 | $235.19 | |
| 97597 | <1% | 27 | $232.45 | |
| 82105 | <1% | 12 | $179.04 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,436 | $163.80 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $162.98 |
| 82947 | <1% | 31 | $135.94 | |
| 82570 | <1% | 13 | $46.10 | |
| 94761 | <1% | 77 | $38.58 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 83 | $24.18 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,045 | $10.79 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17 | $6.08 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 204 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 88 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 70 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 13 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 78 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 164 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 25 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 27 | $0.00 |
| 36416 | 0% | 80 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 15 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 36 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 16 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARMONING, TAMMI (CFO)
| Provider | Location | Paid |
|---|---|---|
| Mercy Hospital Ada, INC | Ada, OK | $10.49M |
| Mercy Hospital Ada, INC | Ada, OK | $4.58M |
| Mercy Hospital Rogers | Rogers, AR | $142K |
| Mercy Hospital Ardmore, INC | Ardmore, OK | $75K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.